Sarah Dunn
Dr Sarah Dunn is a Director in Cell Line Development and Engineering at AstraZeneca, based in Cambridge, UK. Sarah has over 10 years’ experience in generating mammalian cell lines for the production of biotherapeutics including antibodies, multi-specific formats and fusion proteins. Sarah is excited to identify new opportunities to accelerate the delivery of life-changing medicines to patients.